Kooij Louise Frederika

Chief Accounting OfficerNewAmsterdam Pharma Co N.V. (NAMS) · full profile →Form 4 · filed Jun 24, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.2M
Net Open-Market Flow
-$1.2M
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 22, 2026Option exercise(M)25K$10.90$273K49K
Jun 22, 2026Option exercise(M)15K$11.90$179K64K
Jun 22, 2026Sell(S)40K$30.20$1.2M25K
Jun 22, 2026Sell(S)300$30.73$9K24K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 22, 2026Option exercise(M)25K$043K
Jun 22, 2026Option exercise(M)15K$035K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-281062) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.